What is the current stock price of ALX Oncology Holdings Inc. (ALXO)?

As of the latest market data, ALX Oncology Holdings Inc. (ALXO) is trading at $1.70. The stock has seen a loss of 0.00% today.

Does ALX Oncology Holdings Inc. (ALXO) pay a dividend?

Based on current data, ALX Oncology Holdings Inc. does not have a confirmed active dividend policy.

What is the market cap of ALX Oncology Holdings Inc.?

The current market capitalization of ALX Oncology Holdings Inc. (ALXO) is approximately unavailable.

ALXO

ALX Oncology Holdings Inc.·Healthcare

1.70

0.000%(+0.00)

Market Closed

1.82

7.059%(+0.12)

After Hours

Last Updated: — ET

52W L: $0.4052W H: $2.66

ALXO NEWS

defenseworld.net

Mar 2

ALX Oncology Q4 Earnings Call Highlights

ALX Oncology (NASDAQ: ALXO) outlined progress across its two core programs-CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate ALX2004-while providing updated clinical timelines and financial runway during its fourth-quarter and full-year 2025 results call. Leadership update and execution focus Chief Executive Officer Jason Lettmann said the company's priority remains execution and positioned 2025 as a year that

seekingalpha.com

Feb 27

ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript

globenewswire.com

Feb 27

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers - - Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Cancer 2026 Annual Congress - - Phase 2 ASPEN-09 breast cancer trial is currently enrolling patients and will evaluate evorpacept efficacy by CD47 expression levels, with topline data anticipated mid-2027 - - Phase 1 trial evaluating ALX2004 continues to enroll patients in the third dose cohort; safety data from dose-escalation phase expected in 2H 2026 - - Company completed a $150 million registered offering of common stock and pre-funded warrants, extending cash runway through 1H 2028 inclusive of key clinical program milestones for evorpacept and ALX2004 - - Barbara Klencke, M.D., appointed to Chief Medical Officer on a permanent basis - - Company to host webcast on Friday, February 27, at 5:30 a.m.

globenewswire.com

Feb 19

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit.

globenewswire.com

Feb 19

ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release.

zacks.com

Feb 9

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?

Here is how ALX Oncology Holdings Inc. (ALXO) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2020-07-17

Beta

0.50

Websitewww.alxoncology.com↗